360 related articles for article (PubMed ID: 36982978)
1. Antiretroviral Treatment of HIV-2 Infection: Available Drugs, Resistance Pathways, and Promising New Compounds.
Moranguinho I; Taveira N; Bártolo I
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982978
[TBL] [Abstract][Full Text] [Related]
2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
3. Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.
Taiwo B; Murphy RL; Katlama C
Drugs; 2010 Sep; 70(13):1629-42. PubMed ID: 20731472
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection.
Menéndez-Arias L; Alvarez M
Antiviral Res; 2014 Feb; 102():70-86. PubMed ID: 24345729
[TBL] [Abstract][Full Text] [Related]
5. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
Joly V; Yeni P
Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
[TBL] [Abstract][Full Text] [Related]
6. Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era.
Boyd MA; Hill AM
Pharmacoeconomics; 2010; 28 Suppl 1():17-34. PubMed ID: 21182341
[TBL] [Abstract][Full Text] [Related]
7. Drug resistance prevalence and HIV-1 variant characterization in the naive and pretreated HIV-1-infected paediatric population in Madrid, Spain.
de Mulder M; Yebra G; Martín L; Prieto L; Mellado MJ; Rojo P; Muñoz-Fernández MÁ; Jiménez de Ory S; Ramos JT; Holguín A;
J Antimicrob Chemother; 2011 Oct; 66(10):2362-71. PubMed ID: 21810838
[TBL] [Abstract][Full Text] [Related]
8. Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa.
Gottlieb GS; Badiane NM; Hawes SE; Fortes L; Toure M; Ndour CT; Starling AK; Traore F; Sall F; Wong KG; Cherne SL; Anderson DJ; Dye SA; Smith RA; Mullins JI; Kiviat NB; Sow PS;
Clin Infect Dis; 2009 Feb; 48(4):476-83. PubMed ID: 19143530
[TBL] [Abstract][Full Text] [Related]
9. The development of anti-HIV-1 drugs.
Lu XF; Chen ZW
Yao Xue Xue Bao; 2010 Feb; 45(2):165-76. PubMed ID: 21348415
[TBL] [Abstract][Full Text] [Related]
10. Profile of drug resistance mutations among HIV-1-infected Tunisian subjects failing antiretroviral therapy.
Jlizi A; Ben Ammar El Gaaied A; Slim A; Tebourski F; Ben Mamou M; Ben Chaabane T; Letaief-Omezzine A; Chakroun M; Garbouj M; Ben Rejeb S
Arch Virol; 2008; 153(6):1103-8. PubMed ID: 18483694
[TBL] [Abstract][Full Text] [Related]
11. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
12. Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial nonsuppressive highly active antiretroviral therapy.
Agwu A; Lindsey JC; Ferguson K; Zhang H; Spector S; Rudy BJ; Ray SC; Douglas SD; Flynn PM; Persaud D;
AIDS Patient Care STDS; 2008 Jul; 22(7):545-52. PubMed ID: 18479228
[TBL] [Abstract][Full Text] [Related]
13. New antiretroviral drugs.
Gulick RM
Clin Microbiol Infect; 2003 Mar; 9(3):186-93. PubMed ID: 12667250
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis, antiretroviral therapy, and emergence of resistance to antiretroviral agents in HIV-2 infection: a review.
Hightower M; Kallas EG
Braz J Infect Dis; 2003 Feb; 7(1):7-15. PubMed ID: 12807687
[TBL] [Abstract][Full Text] [Related]
15. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
16. Treatment limitations imposed by antiretroviral drug resistance mutations: implication for choices of first line regimens in resource-limited settings.
Mtambo A; Chan K; Shen A; Lima V; Hogg R; Montaner J; Moore D
HIV Med; 2012 Mar; 13(3):141-7. PubMed ID: 22107262
[TBL] [Abstract][Full Text] [Related]
17. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
Joly V; Descamps D; Yeni P
AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 antiretroviral drug therapy.
Arts EJ; Hazuda DJ
Cold Spring Harb Perspect Med; 2012 Apr; 2(4):a007161. PubMed ID: 22474613
[TBL] [Abstract][Full Text] [Related]
19. New antiretroviral drugs.
Hanson K; Hicks C
Curr HIV/AIDS Rep; 2006 Jul; 3(2):93-101. PubMed ID: 16608666
[TBL] [Abstract][Full Text] [Related]
20. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
